- Home
- JBLU vs TNGX Comparison
JBLU vs TNGX Comparison
Compare JBLU & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBLU | TNGX |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JBLU | TNGX |
|---|---|---|
| Price | $4.91 | $9.12 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $4.76 | ★ $12.50 |
| AVG Volume (30 Days) | ★ 16.9M | 2.7M |
| Earning Date | 01-27-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,095,000,000.00 | $66,501,000.00 |
| Revenue This Year | N/A | $53.01 |
| Revenue Next Year | $8.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 53.29 |
| 52 Week Low | $3.34 | $1.03 |
| 52 Week High | $8.31 | $11.20 |
Technical Indicators
Market Signals| Indicator | JBLU | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 61.63 | 49.09 |
| Support Level | $4.67 | $8.89 |
| Resistance Level | $5.15 | $10.22 |
| Average True Range (ATR) | 0.22 | 0.62 |
| MACD | 0.05 | -0.15 |
| Stochastic Oscillator | 74.74 | 10.83 |
Price Performance
Historical ComparisonAbout JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.